Prescribed Into Peril: How Psychiatric Medications Can Quietly Undermine Addiction Recovery

There is a painful irony embedded in the treatment of dual diagnosis: the very medications intended to stabilize a patient's mental health can, under certain prescribing conditions, destabilize their recovery from addiction. This is not a fringe concern or a rare edge case. It is a systemic vulnerability that affects a substantial portion of the estimated 21.5 million Americans living with co-occurring mental health and substance use disorders, according to data from the Substance Abuse and Mental Health Services Administration (SAMHSA).

Understanding why this happens—and how to prevent it—requires a clear-eyed look at both the pharmacology of commonly prescribed psychiatric drugs and the structural gaps in how American clinicians are trained to use them.

The Prescribing Gap: When Mental Health Expertise and Addiction Medicine Don't Overlap

Primary care physicians manage a significant share of psychiatric prescriptions in the United States. A 2022 analysis published in Psychiatric Services found that nearly half of all antidepressant and anxiolytic prescriptions are written by non-psychiatrist physicians. While many of these providers are competent managers of straightforward mental health conditions, their training in addiction pharmacology is frequently limited.

Board certification in psychiatry does not automatically confer expertise in addiction medicine, and vice versa. The two specialties have historically operated in separate silos—a structural reality that mirrors the fragmented care systems that complicate dual diagnosis treatment more broadly. A psychiatrist may be highly skilled at titrating mood stabilizers but less attuned to the relapse risk profiles of specific drug classes. An addiction medicine specialist may understand dependence mechanisms deeply but lack the clinical confidence to manage complex mood disorders.

The result is a prescribing environment where patients with dual diagnosis frequently fall through the cracks between two disciplines that rarely communicate with sufficient depth.

Benzodiazepines: The Most Visible Flashpoint

No medication class illustrates this problem more starkly than benzodiazepines. Drugs such as alprazolam (Xanax), lorazepam (Ativan), and clonazepam (Klonopin) are among the most effective short-term treatments for anxiety disorders and acute panic. They are also among the most habit-forming substances available by prescription.

For a patient with a history of alcohol use disorder or sedative dependence, benzodiazepines represent a pharmacologically adjacent risk. Both alcohol and benzodiazepines act on GABA-A receptors; a patient with prior alcohol dependence has, in effect, already primed their neurological reward system to respond powerfully to GABAergic compounds. Prescribing a benzodiazepine to such a patient without careful consideration of this history is not simply suboptimal—it can initiate a new substance use disorder within weeks.

Clinical cases bear this out. Consider a composite scenario that reflects patterns well-documented in addiction literature: a 38-year-old woman with generalized anxiety disorder and five years of alcohol sobriety presents to a new primary care physician following a job loss. She is prescribed clonazepam for acute anxiety management. Within three months, she is taking twice her prescribed dose. Within six months, she is drinking again. Neither her sobriety history nor her anxiety diagnosis was treated as part of an integrated clinical picture.

Safer alternatives exist. Buspirone, certain SSRIs and SNRIs, and hydroxyzine can address anxiety in patients with addiction histories with substantially lower abuse potential. Prescribers willing to engage with addiction pharmacology literature will find a robust evidence base for these substitutions.

Stimulants, ADHD, and the Stimulant Use Disorder Overlap

Attention-deficit/hyperactivity disorder (ADHD) and stimulant use disorder co-occur at rates that demand clinical attention. Research published in the Journal of Clinical Psychiatry has consistently demonstrated that individuals with stimulant use disorders—including cocaine and methamphetamine dependence—show elevated rates of ADHD diagnoses. The mechanistic connection is not coincidental: both cocaine and prescription amphetamines act on dopaminergic and noradrenergic pathways.

When a patient with a history of stimulant use disorder is prescribed amphetamine-based ADHD medications such as Adderall or Vyvanse, the prescribing rationale may be entirely sound—ADHD is a genuine and impairing condition that warrants treatment. However, the pharmacological overlap creates a meaningful risk of misuse, diversion, or reinstatement of prior stimulant-seeking behavior.

Non-stimulant ADHD treatments—atomoxetine (Strattera), guanfacine (Intuniv), and bupropion—offer clinically meaningful alternatives for patients in this population. The efficacy profiles of these medications are generally lower than amphetamine-based treatments, and this is a legitimate clinical trade-off that requires honest conversation between patient and provider. That conversation, however, must actually take place.

Opioids in Co-Occurring Pain and Addiction

Chronic pain is disproportionately prevalent among individuals with substance use disorders, in part because of shared neurobiological vulnerabilities and in part because addiction itself can cause or exacerbate pain conditions. When a patient with opioid use disorder presents with legitimate chronic pain, the clinical calculus becomes extraordinarily difficult.

Prescribing opioid analgesics to a patient with a documented opioid use disorder history is, in many cases, contraindicated. Yet undertreated pain is itself a relapse driver. Non-opioid analgesics, physical therapy, nerve block procedures, and medications such as gabapentin or duloxetine may offer partial relief, though they are not universally effective. In some clinical contexts, carefully monitored opioid therapy with addiction medicine co-management may represent the most humane and evidence-supported option.

The critical point is not that opioids must always be avoided—it is that their use in this population demands a level of pharmacological vigilance and interdisciplinary coordination that routine prescribing practice rarely provides.

Advocating for Safer Prescribing: A Practical Guide for Patients and Families

Knowing that these risks exist is the first step. Knowing how to act on that knowledge is the second.

Disclose the full history, every time. Patients and families should treat addiction history as essential medical information—not a source of shame to be minimized. Every prescriber, including urgent care physicians and telehealth providers, should know about prior substance use disorders before any new medication is initiated.

Ask the direct question. Before accepting a new prescription, patients are entitled to ask: Does this medication have abuse potential? Are there alternatives with lower addiction risk that would address my condition? A prescriber who dismisses this question is a prescriber who may not be the right fit for dual diagnosis care.

Request integrated care or formal consultation. When a patient is under the care of both a psychiatrist and an addiction specialist, those providers should be communicating. If they are not, patients and families can formally request care coordination—and document that request.

Use PDMP resources. Most states operate Prescription Drug Monitoring Programs (PDMPs) that track controlled substance prescriptions. Patients can ask their providers to review PDMP records as part of routine prescribing practice, a step that reduces the risk of unintentional polypharmacy.

Seek providers with dual diagnosis training. The American Society of Addiction Medicine (ASAM) and the American Academy of Addiction Psychiatry (AAAP) maintain provider directories. Seeking clinicians with credentials in both psychiatric care and addiction medicine is not an unreasonable standard—it is the standard this patient population deserves.

Moving Toward a More Accountable Prescribing Culture

The medication maze that dual diagnosis patients navigate is not inevitable. It is the product of fragmented training systems, siloed clinical cultures, and a healthcare infrastructure that has historically treated addiction and mental illness as separate problems requiring separate solutions.

Pharmacological safety in dual diagnosis care is achievable. It requires prescribers who approach every patient with an addiction history as a patient requiring a modified risk calculus—not a patient to be avoided or undertreated, but one whose care demands greater precision, greater collaboration, and greater humility about the limits of any single clinician's expertise.

For patients and families already inside the maze, the path forward begins with information: knowing the risks, naming them clearly, and refusing to accept prescribing practices that treat a complex history as invisible.